http://jpet.aspetjournals.org/content/jpet/371/1/1.full.pdf … This is big news; an antipsychotic that's NOT a D2 agonist.
-
-
I learned about this from Emer Leahy, the founder of Psychogenics, the biotech company that built the SmartCube and pioneered this behavioral-phenotype approach to CNS drug discovery. It sounded crazy 20 years ago, but now the results are coming in and they're astonishing.
Show this thread -
In vivo phenotypic screening: it's how you do exploratory science when computing power is abundant! And it works! (Hint: we're doing it at Daphnia Labs too.)
Show this thread
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.